Related Experiment Video
Updated: Apr 28, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Targeting cytokine networks in KRAS-driven tumorigenesis
Hadrien G Golay1, David A Barbie
1Department of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
KRAS mutations drive aggressive cancers and resist direct targeting. New therapies disrupting cytokine signaling networks offer a promising strategy to overcome treatment resistance in KRAS-driven tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- KRAS is a frequently mutated oncogene in human cancers, often linked to poor prognosis.
- Directly inhibiting KRAS has proven challenging, leading to strategies targeting downstream pathways like RAF/MEK and PI3K/AKT.
- Previous combination therapies targeting these downstream pathways have yielded suboptimal clinical results.
Discussion:
- This review highlights cytokine signaling circuitry as a viable therapeutic target in KRAS-driven tumors.
- Evidence suggests that targeting these cytokine networks can disrupt tumor growth and survival mechanisms.
- This approach offers a novel avenue for overcoming resistance to current KRAS-targeted therapies.
Key Insights:
- KRAS-driven tumors possess a unique cytokine signaling dependency.
- Targeting cytokine networks presents a tractable strategy for KRAS-mutant cancers.
- Novel therapeutics aimed at cytokine signaling may circumvent resistance to conventional treatments.
Outlook:
- Developing novel therapeutics that disrupt cytokine signaling is crucial for advancing KRAS-targeted therapy.
- This approach holds potential for overcoming treatment resistance in a significant subset of human cancers.
- Further research into KRAS-cytokine interactions could unlock new therapeutic opportunities.
More Related Videos
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
11:00Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
Published on: June 23, 2023
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...